1. Scrip
  2. >>Business

Zymergen Buy Will Enhance Ginkgo’s Services, Accelerate Growth

Deal Valued At $300m

 
• By Mandy Jackson

Troubled Zymergen will continue its ongoing restructuring efforts and Ginkgo, which has seen its own challenges since going public, will use Zymergen’s automation expertise to accelerate its growth.

The magnet attracts figures from the crowd. Talent acquisition concept.
Ginkgo will bring on Zymergen's automation experts but two other business units are being spun out • Source: Shutterstock

Two service providers with similar offerings for biopharmaceutical, industrial, cosmetic and agricultural clients – Ginkgo Bioworks and Zymergen, Inc. – will combine under one name as Ginkgo takes advantage of difficult financial market conditions to acquire Zymergen in an all-stock transaction.

Both companies use synthetic biology and other technologies to enable more efficient drug development and manufacturing, and provide similar services for other industries. They said on 25 July that Zymergen shareholders will receive 0.9179 shares of Ginkgo for every share of Zymergen that they own, giving the firm’s shareholders 5

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.